Patrick Costello
YOU?
Author Swipe
View article: Penetrant PKCβ mutation in ATLL displays a mixed gain-of-function
Penetrant PKCβ mutation in ATLL displays a mixed gain-of-function Open
Mutations in the T-cell receptor signalling pathway have been identified in patients with adult T-cell leukaemia/lymphoma (ATLL) and one of the most frequently observed targets of these mutations is protein kinase C beta (PKCβ). Here, we h…
View article: Enhanced Risk Stratification of Smoldering Multiple Myeloma with Dynamic Biomarkers: A Multinational, Multicenter Study including 2,270 Participants (PANGEA 2.0)
Enhanced Risk Stratification of Smoldering Multiple Myeloma with Dynamic Biomarkers: A Multinational, Multicenter Study including 2,270 Participants (PANGEA 2.0) Open
Accurate prediction of risk of progression from smoldering (SMM) to active multiple myeloma (MM) is paramount to individualized early therapeutic strategies with minimum risk of overtreatment. Current risk stratification models do not acco…
View article: Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma
Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma Open
Chimeric antigen receptor (CAR) T-cell (CAR-T) therapy represents a major advance in the treatment of relapsed/refractory multiple myeloma (RRMM). However, the long time span from leukapheresis to actual CAR-T infusion often necessitates b…
View article: Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants
Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants Open
Background The 20/2/20 model is the current gold standard to stratify smoldering multiple myeloma (SMM) patients at baseline into three subgroups (low, intermediate, and high) according to the risk of progression based on the free light ch…
View article: Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel Open
*Authors contributed equally. Introduction. Two chimeric antigen receptor (CAR) T-cell therapies have been FDA approved for patients with relapsed/refractory multiple myeloma (RRMM): idecabtagene vicleucel (ide-cel) and ciltacabtagene auto…
View article: Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma Open
Introduction. Ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel), two anti-B-cell maturation antigen (BCMA) CAR T therapies, have demonstrated remarkable responses and improved survival among patients with relapsed/…
View article: Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma Open
Ciltacabtagene autoleucel (cilta-cel) was approved in 2022 for patients with relapsed/refractory multiple myeloma (RRMM). We report outcomes with cilta-cel in the standard-of-care setting. Patients with RRMM who underwent leukapheresis for…
View article: EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma
EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma Open
Background Chimeric antigen receptor (CAR) T-cell therapy has demonstrated significant benefits in the treatment of relapsed/refractory multiple myeloma (RRMM). However, these outcomes can be compromised by severe complications, including …
View article: Burkitt lymphoma: interpreting FISH testing for <i>MYC</i> gene rearrangements
Burkitt lymphoma: interpreting FISH testing for <i>MYC</i> gene rearrangements Open
Burkitt lymphoma is a highly aggressive B cell non-Hodgkin’s lymphoma characterised by translocation of MYC gene on chromosome 8. This translocation is usually detected by fluorescent in-situ hybridisation (FISH) studies as part of routine…
View article: A Rare Case of Sarcoidosis Involving Male Breast Tissue
A Rare Case of Sarcoidosis Involving Male Breast Tissue Open
Sarcoidosis is a multisystem, inflammatory granulomatous disease that rarely involves breast tissue. The pathophysiology of this chronic granulomatous condition is not well understood but is thought to be multifactorial, involving environm…
View article: Chronic mast cell leukaemia with exon 9 <i>KIT</i> mutation A502_Y503dup: a rare imatinib responsive variant
Chronic mast cell leukaemia with exon 9 <i>KIT</i> mutation A502_Y503dup: a rare imatinib responsive variant Open
Mast cell leukaemia (MCL) is a very rare aggressive form of systemic mastocytosis (SM), representing <1% of cases of adult SM in the USA. The diagnosis of MCL requires the presence of SM criteria accompanied by mast cells accounting for at…
View article: Thymic basaloid carcinoma: a rare clinical entity
Thymic basaloid carcinoma: a rare clinical entity Open
Primary thymic carcinoma is a rare malignancy and particularly basaloid type is an even rare subtype, with less than 20 cases published as individual case reports in the English literature.[1–5][1] A 61-year-old female patient presented af…
View article: 17 Caring for the palliative medicine multidisciplinary team: piloting an emotional support forum
17 Caring for the palliative medicine multidisciplinary team: piloting an emotional support forum Open
Background Working in palliative medicine requires emotional resilience and is associated with compassion fatigue and burnout. However, research into support strategies for palliative care teams is lacking. Schwartz rounds improve caregive…